399 related articles for article (PubMed ID: 35111149)
1. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
Front Immunol; 2021; 12():719105. PubMed ID: 35111149
[TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
[TBL] [Abstract][Full Text] [Related]
4. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
Front Immunol; 2021; 12():649061. PubMed ID: 33986743
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
Yang B; Zhou M; Wu Y; Ma Y; Tan Q; Yuan W; Ma J
Front Immunol; 2021; 12():769047. PubMed ID: 34777388
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
Front Immunol; 2021; 12():790661. PubMed ID: 34925373
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
8. A quantitative score of immune cell infiltration predicts the prognosis in pancreatic ductal adenocarcinoma.
Chen ZG; Wang Y; Fong WP; Hu MT; Liang JY; Wang L; Li YH
Int Immunopharmacol; 2021 Sep; 98():107890. PubMed ID: 34174701
[TBL] [Abstract][Full Text] [Related]
9. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
[TBL] [Abstract][Full Text] [Related]
10. IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma.
Fan L; Wang X; Chang Q; Wang Y; Yang W; Liu L
Medicine (Baltimore); 2022 Oct; 101(42):e30966. PubMed ID: 36281157
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer.
Lu Q; Zhang Y; Chen X; Gu W; Ji X; Chen Z
Medicine (Baltimore); 2021 Mar; 100(12):e24957. PubMed ID: 33761652
[TBL] [Abstract][Full Text] [Related]
12. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.
Knudsen ES; Vail P; Balaji U; Ngo H; Botros IW; Makarov V; Riaz N; Balachandran V; Leach S; Thompson DM; Chan TA; Witkiewicz AK
Clin Cancer Res; 2017 Aug; 23(15):4429-4440. PubMed ID: 28348045
[No Abstract] [Full Text] [Related]
13. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
14. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
15. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
[TBL] [Abstract][Full Text] [Related]
16. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma.
Wang D; Cui SP; Chen Q; Ren ZY; Lyu SC; Zhao X; Lang R
BMC Cancer; 2023 Jun; 23(1):601. PubMed ID: 37386391
[TBL] [Abstract][Full Text] [Related]
17. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
18. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
19. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
Front Immunol; 2021; 12():774435. PubMed ID: 35046938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
